However, the inactivation of MARCKS is commonly observed in human colon cancers and associated with adverse patient outcomes, suggesting that MARCKS acts as a suppressor of progression in human colorectal cancer [56]. This evidence concerns the gene MARCKS and colonic neoplasm.